% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Platten:132944,
      author       = {M. Platten$^*$ and L. Bunse$^*$ and D. Riehl$^*$ and T.
                      Bunse$^*$ and K. Ochs$^*$ and W. Wick$^*$},
      title        = {{V}accine {S}trategies in {G}liomas.},
      journal      = {Current treatment options in neurology},
      volume       = {20},
      number       = {5},
      issn         = {1534-3138},
      address      = {Philadelphia, Pa.},
      publisher    = {Current Science Inc.},
      reportid     = {DKFZ-2018-00583},
      pages        = {11},
      year         = {2018},
      abstract     = {To discuss the current state of glioma vaccine development
                      and highlight the challenges associated with clinical
                      implementation of these approaches.Vaccination strategies
                      against gliomas have matured considerably during the past
                      years, although proof-of efficacy from controlled clinical
                      trials is still lacking. Advances in antigen discovery,
                      including the definition of neoepitopes including epidermal
                      growth factor receptor variant III (EGFRvIII), isocitrate
                      dehydrogenase (IDH)1R132H and Histone (H)3.3K27M, using
                      multi-omic approaches and computational algorithms allow
                      targeting single antigens, but also implementing truly
                      personalized approaches. In addition, new concepts of
                      vaccine manufacturing including RNA and DNA vaccines improve
                      immunogenicity and applicability in personalized settings.
                      As an increasing amount of clinical data defy the concept of
                      the central nervous system (CNS) as a strictly
                      immunoprivileged site, novel vaccine approaches enter the
                      clinic including critical efforts to identify biomarkers of
                      response and resistance and strategies to overcome the
                      immunosuppressive glioma microenvironment.},
      subtyp        = {Review Article},
      cin          = {G160 / L101 / G808 / G370},
      ddc          = {610},
      cid          = {I:(DE-He78)G160-20160331 / I:(DE-He78)L101-20160331 /
                      I:(DE-He78)G808-20160331 / I:(DE-He78)G370-20160331},
      pnm          = {317 - Translational cancer research (POF3-317)},
      pid          = {G:(DE-HGF)POF3-317},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:29594595},
      doi          = {10.1007/s11940-018-0498-1},
      url          = {https://inrepo02.dkfz.de/record/132944},
}